Rosuvastatin (Calcium)

Rosuvastatin (Calcium)

• CAS Number: 147098-20-2
• UNSPSC Description: Rosuvastatin Calcium is a competitive HMG-CoA reductase (HMGCR) inhibitor, with an IC50 of 11 nM. Rosuvastatin Calcium potently blocks hERG current with an IC50 of 195 nM[2]. Rosuvastatin Calcium reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin Calcium effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels[1][2][3].
• Target Antigen: Autophagy; Bacterial; HMG-CoA Reductase (HMGCR); Potassium Channel
• Type: Reference compound
• Related Pathways: Anti-infection;Autophagy;Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease
• Applications: Cancer-programmed cell death
• Field of Research: Metabolic Disease; Cardiovascular Disease; Cancer
• Assay Protocol: https://www.medchemexpress.com/Rosuvastatin-Calcium.html
• Solubility: DMSO : 25 mg/mL (ultrasonic)|H2O : 1 mg/mL (ultrasonic)
• Smiles: O=C([O-])C[C@H](O)C[C@H](O)/C=C/C1=C(C(C)C)N=C(N(C)S(=O)(C)=O)N=C1C2=CC=C(F)C=C2.[0.5Ca2+]
• Molecular Weight: 500.57
• References & Citations: [1]Watanabe, M., et al., Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem, 1997. 5(2): p. 437-44.|[2]Plante I, et al. Rosuvastatin blocks hERG current and prolongs cardiac repolarization. J Pharm Sci. 2012 Feb;101(2):868-78.|[3]Feng PF, et al. Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane. Mol Pharm. 2019 Apr 1;16(4):1477-1488.|[4]Carswell C.I., et al. Rosuvastatin. Drugs, 2002. 62(14): p. 2075-85; discussion 2086-7.Acta Pharmacol Sin. 2023 Jan 31.|Adv Sci (Weinh). 2024 Jul 5:e2403451.|bioRxiv. 2024 November 08.|Cell Death Discov. 2024 May 29;10(1):263.|Front Bioeng Biotechnol. 2022 Mar 17;10:826093.|Front Cell Dev Biol. 2022 Mar 3;10:806081.|MedComm. 2024 Aug 31.|Eur J Pharmacol. 2023 Jul 13;955:175911.|Exp Ther Med. August 17, 2021.|Front Cell Dev Biol. 2021 May 6;9:651579.|Front Oncol. 10 May 2021.|Front Oncol. 2021 May 10;11:595285.|J Inflamm Res. 2021,14: 1537-1549.|Phytomedicine. 2024 Apr 10, 155621.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched